NeoPhore

NeoPhore is a UK immuno-oncology company developing first-in-class small molecule inhibitors of the DNA mismatch repair pathway.

By transiently blocking MMR, the company's compounds render tumours MMR-deficient and immunogenic, generating neoantigens that stimulate immune responses against cancer.

The approach aims to extend the benefit of existing immunotherapies to patients with solid tumours that do not currently respond.

NeoPhore's pipeline targets multiple proteins across the MMR pathway